Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Non-Current Deffered Revenue (2016 - 2018)

NovaBay Pharmaceuticals (NBY) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $184000.0 as the latest value for Q4 2018.

  • On a quarterly basis, Non-Current Deffered Revenue fell 48.17% to $184000.0 in Q4 2018 year-over-year; TTM through Dec 2018 was $184000.0, a 48.17% decrease, with the full-year FY2018 number at $184000.0, down 48.17% from a year prior.
  • Non-Current Deffered Revenue was $184000.0 for Q4 2018 at NovaBay Pharmaceuticals, down from $213000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $3.1 million in Q1 2016 to a low of $155000.0 in Q2 2014.
  • A 5-year average of $600750.0 and a median of $225000.0 in 2018 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: plummeted 89.03% in 2015, then surged 1669.89% in 2016.
  • NovaBay Pharmaceuticals' Non-Current Deffered Revenue stood at $171000.0 in 2014, then increased by 10.53% to $189000.0 in 2015, then surged by 73.02% to $327000.0 in 2016, then grew by 8.56% to $355000.0 in 2017, then crashed by 48.17% to $184000.0 in 2018.
  • Per Business Quant, the three most recent readings for NBY's Non-Current Deffered Revenue are $184000.0 (Q4 2018), $213000.0 (Q3 2018), and $237000.0 (Q2 2018).